All In Biotech

NDA 020064 · Almatica

Macrobid

Nitrofurantoin, Nitrofurantoin, Macrocrystalline · Oral · Nitrofuran Antibacterial

Last checked: Nov 19, 2026Latest source record: Mar 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Dec 24, 1991

Approved uses

1

Original approval plus efficacy supplements

Registered trials

78

11 Phase 3, 18 recruiting

FAERS reports

5,883

4,020 serious, 335 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 24, 2026.

INDICATIONS AND USAGE Nitrofurantoin capsules (monohydrate/macrocrystals) are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus . Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (monohydrate/macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (monohydrate/macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (monohydrate/macrocrystals) are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES . ) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (monohydrate/macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (monohydrate/macrocrystals) lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of...

Mechanism: Mechanism of Action The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other macromolecules. As a result of such inactivations, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. Nitrofurantoin is bactericidal in urine at therapeutic doses. The broad-based nature of this mode of action may explain the lack of acquired...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 24, 1991 Original approval · Type 3 - New Dosage Form
1 products under this application
  • MACROBID · NITROFURANTOIN 75MG; NITROFURANTOIN, MACROCRYSTALLINE 25MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitrofurantoin" as an intervention, any sponsor and status, largest first.

All 78 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urinary tract infection820
  • headache623
  • nausea590
  • drug hypersensitivity552
  • fatigue537
  • pain505
  • dyspnoea444
  • drug ineffective438
  • off label use398
  • diarrhoea373
  • dizziness370
  • vomiting347

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200485
200583
2006103
200780
200899
2009126
2010177
2011249
2012274
2013227
2014329
2015385
2016500
2017406
2018400
2019432
2020469
2021294
2022255
2023249
2024229
2025261
2026171

Recalls

3 FDA enforcement reports for this application.

  • Jul 24, 2019 · Class II · Terminated

    Failed dissolution specifications

  • Jul 24, 2019 · Class II · Terminated

    Failed dissolution specifications

  • Apr 21, 2015 · Class II · Terminated

    Failed Dissolution Specification; 6 month time point

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Macrobid (Nitrofurantoin Monohyd/M-Cryst)

2024 spending

$75K

Beneficiaries

399

590 claims

Per beneficiary

$188

$5.65 per unit

View as table
YearSpending
2020$79,074
2021$53,957
2022$57,114
2023$63,981
2024$74,940

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 229 on PubMed

Sponsor: Almatica

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.